Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Published by: GBI Research

Published: Oct. 15, 2011 - 223 Pages


Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Anti-Inflammatory Therapeutics Market to 2017: Introduction
2.1 GBI Research Report Guidance
3 Anti-Inflammatory Therapeutics Market to 2017: Market Overview
3.1 Introduction
3.1.1 Revenue
3.1.2 Branded Vs Generics
3.1.3 Annual Cost of Treatment
3.1.4 Treatment Usage Pattern
4 Anti-Inflammatory Therapeutics Market to 2017: Geographical Landscape
4.1 Revenue Analysis by Geography
4.2 The US
4.2.1 Revenue
4.2.2 Annual Cost of Treatment
4.2.3 Treatment Usage Patterns
4.3 Top Five Countries of Europe
4.3.1 Revenue
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Patterns
4.4 Japan
4.4.1 Revenue
4.4.2 Annual Cost of Treatment
4.4.3 Treatment Usage Patterns
5 Anti-Inflammatory Therapeutics Market to 2017: Therapeutic Landscape
5.1 Respiratory Diseases
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Treatment
5.1.4 Treatment Usage Pattern
5.2 Drivers and Barriers the Respiratory Therapeutics Market
5.2.1 Drivers for Respiratory Therapeutics Market
5.2.2 Barriers for Respiratory Therapeutics Market
5.3 Arthritis Therapeutics Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Treatment
5.3.4 Treatment Usage Pattern
5.4 Drivers and Barriers for Arthritis Therapeutics Market
5.4.1 Drivers for Arthritis Therapeutics Market
5.4.2 Barriers for Arthritis Therapeutics Market
5.5 Multiple Sclerosis Therapeutics
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Treatment
5.5.4 Treatment Usage Pattern
5.6 Drivers and Barriers for Multiple Sclerosis Therapeutics Market
5.6.1 Drivers for Multiple Sclerosis Therapeutics Market
5.6.2 Barriers for Multiple Sclerosis Therapeutics Market
5.7 Psoriasis Therapeutics Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost of Treatment
5.7.4 Treatment Usage Pattern
5.8 Drivers and Barriers for Psoriasis Therapeutics Market
5.8.1 Drivers for Psoriasis Therapeutics Market
5.8.2 Barriers for Psoriasis Therapeutics Market
5.9 Spondyloarthropathies Therapeutics Market
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Treatment Usage Pattern
5.10 Drivers and Barriers for Spondyloarthropathies Therapeutics Market
5.10.1 Drivers for Spondyloarthropathies Therapeutics Market
5.10.2 Barriers for Spondyloarthropathies Therapeutics Market
5.11 Inflammatory Bowel Disease
5.11.1 Introduction
5.11.2 Revenue
5.11.3 Annual Cost of Treatment
5.11.4 Treatment Usage Pattern
5.12 Drivers and Barriers for IBD Therapeutics Market
5.12.1 Drivers the IBD Therapeutics Market
5.12.2 Barriers for IBD Therapeutics Market
5.13 Gout Therapeutics Market
5.13.1 Introduction
5.13.2 Revenue
5.13.3 Annual Cost of Treatment (ACT)
5.13.4 Treatment Usage Pattern
5.14 Drivers and Barriers for Gout Therapeutics Market
5.14.1 Drivers for Gout Therapeutics Market
5.14.2 Barriers for Gout Therapeutics Market
6 Anti-Inflammatory Therapeutics Market to 2017: Pipeline Analysis
6.1 Introduction
6.2 Anti-Inflammatory Therapeutics Market to 2017 - Pipeline Assessment by Clinical Phase of Development
6.2.1 Filed Molecules
6.2.2 Phase III
6.2.3 Phase II
6.2.4 Phase I
6.2.5 Preclinical Phase
6.2.6 Discovery Phase
6.3 Anti-Inflammatory Therapeutics Market to 2017 - Profiles of Promising Molecules
6.3.1 Indacaterol
6.3.2 BTR-15K
6.3.3 Flutiform
6.3.4 Iguratimod
6.3.5 OHR/AVR118
6.3.6 Simponi
6.3.7 Zushima
6.3.8 Civanex
6.3.9 Naproxcinod
6.3.10 Gilenia
6.3.11 Cladribine
6.3.12 Fampyra
6.3.13 LAS41002
6.3.14 BTR-15K
6.3.15 XOMA 052
7 Anti-Inflammatory Therapeutics Market to 2017: Competitive Profiling
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Marketed Products
7.1.3 SWOT Analysis
7.2 Amgen Inc.
7.2.1 Company Overview
7.2.2 Marketed Products
7.2.3 SWOT Analysis
7.3 Johnson & Johnson
7.3.1 Company Overview
7.3.2 Marketed Products
7.3.3 SWOT Analysis
7.4 GlaxoSmithKline
7.4.1 Company Overview
7.4.2 Marketed Products
7.5 AstraZeneca
7.5.1 Company Overview
7.5.2 Marketed Products
7.5.3 SWOT Analysis
7.6 Merck
7.6.1 Company Overview
7.6.2 Marketed Products
7.6.3 SWOT Analysis
7.7 Pfizer
7.7.1 Company Overview
7.7.2 Marketed Products
7.7.3 SWOT Analysis
7.8 Boehringer Ingelheim GmbH
7.8.1 Company Overview
7.8.2 Marketed Products
7.8.3 SWOT Analysis
7.9 Sanofi
7.9.1 Company Overview
7.9.2 Marketed Products
7.9.3 SWOT Analysis
8 Anti-Inflammatory Therapeutics Market to 2017: Strategic Consolidations
8.1 M&A Deals
8.1.1 Deals by Year
8.1.2 Deals by Geography
8.1.3 Deals by Value ($)
8.1.4 Merck & Co Completes Merger with Schering-Plough
8.1.5 Pfizer Completes Acquisition of Wyeth
8.1.6 Bayer Acquires Schering
8.2 Licensing Agreements
8.2.1 Deals by Year
8.2.2 Deals by Geography
8.2.3 Deals by Value ($)
8.2.4 Incyte Enters Into Licensing Agreement with Pfizer
8.2.5 Orexo Enters Into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica
8.2.6 Cytos Biotechnology Plans to Enter Into Licensing Agreement for CYT003-QbG10
8.3 Co-Developments
8.3.1 Deals by Year
8.3.2 Deals by Geography
8.3.3 Deals by Value ($)
8.3.4 Galapagos Enters Into Strategic Alliance with Roche Holding
8.3.5 Sepracor Enters Into Co-Development Agreement with Nycomed
8.3.6 Galapagos Extends its Co-Development Agreement with GlaxoSmithKline
8.3.7 Lycera Enters Into Research Agreement with Merck
9 Anti-Inflammatory Therapeutics Market to 2017: Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Therapeutic Landscape
9.3.5 Market Size by Geography
9.3.6 Geographical Landscape
9.3.7 Pipeline Analysis
9.3.8 Competitive Landscape
9.3.9 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources
1.1 List of Tables
Table 1: Anti-Inflammatory Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 2: Anti-Inflammatory Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
Table 3: Anti-Inflammatory Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 4: Anti-Inflammatory Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 5: Anti-Inflammatory Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010
Table 6: Anti-Inflammatory Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017
Table 7: Anti-Inflammatory Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010
Table 8: Anti-Inflammatory Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017
Table 9: Anti-Inflammatory Therapeutics Market, The US, Revenue ($bn), 2002-2010
Table 10: Anti-Inflammatory Therapeutics Market, The US, Revenue Forecast($bn), 2010-2017
Table 11: Anti-Inflammatory Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010
Table 12: Anti-Inflammatory Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017
Table 13: Anti-Inflammatory Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2010
Table 14: Anti-Inflammatory Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2017
Table 15: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010
Table 16: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Forecast ($bn), 2010-2017
Table 17: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Segmentation by Geography ($bn), 2002-2010
Table 18: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Segmentation by Geography ($bn), 2010-2017
Table 19: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010
Table 20: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017
Table 21: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2002-2010
Table 22: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2010-2017
Table 23: Anti-Inflammatory Therapeutics Market, Japan, Revenue ($bn), 2002-2010
Table 24: Anti-Inflammatory Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2017
Table 25: Anti-Inflammatory Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010
Table 26: Anti-Inflammatory Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017
Table 27: Anti-Inflammatory Therapeutics Market, Japan, Treatment Usage Pattern (millions), 2002-2010
Table 28: Anti-Inflammatory Therapeutics Market, Japan, Treatment Usage Pattern (millions), 2010-2017
Table 29: Respiratory Therapeutics Market, Global, Revenues ($bn), 2002-2010
Table 30: Respiratory Therapeutics Market, Global, Revenue Forecast($bn), 2010-2017
Table 31: Respiratory Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
Table 32: Respiratory Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
Table 33: Respiratory Therapeutics Market, Global, Average Cost of Treatment ($), 2002-2010
Table 34: Respiratory Therapeutics Market, Global, Average Cost of Treatment ($), 2010-2017
Table 35: Respiratory Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010
Table 36: Respiratory Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017
Table 37: Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 38: Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
Table 39: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
Table 40: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
Table 41: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 42: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 43: Arthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010
Table 44: Arthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017
Table 45: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 46: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
Table 47: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
Table 48: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
Table 49: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 50: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 51: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2010
Table 52: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2010-2017
Table 53: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 54: Psoriasis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
Table 55: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
Table 56: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
Table 57: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 58: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 59: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010
Table 60: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017
Table 61: Spondyloarthropathies Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 62: Spondyloarthropathies Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
Table 63: Spondyloarthropathies Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
Table 64: Spondyloarthropathies Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
Table 65: Spondyloarthropathies Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 66: Spondyloarthropathies Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 67: Spondyloarthropathies Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010
Table 68: Spondyloarthropathies Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017
Table 69: IBD Therapeutics Market, Global, Revenue ($bn), 2002-2010
Table 70: IBD Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017
Table 71: IBD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Table 72: IBD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Table 73: IBD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 74: IBD Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 75: IBD Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2010
Table 76: IBD Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2010-2017
Table 77: Gout Therapeutics Market, Global, Revenue ($m), 2002-2010
Table 78: Gout Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017
Table 79: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010
Table 80: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017
Table 81: Gout Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010
Table 82: Gout Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017
Table 83: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010
Table 84: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017
Table 85: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules
Table 86: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Phase III
Table 87: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Phase II
Table 88: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Phase I
Table 89: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase
Table 90: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Discovery Phase
1.2 List of Figures
Figure 1: Anti-Inflammatory Therapeutics Market, Global, Therapeutic Market Share (%), 2010
Figure 2: Anti-Inflammatory Therapeutics Market, Global, Revenue ($bn), 2002-2017
Figure 3: Anti-Inflammatory Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 4: Anti-Inflammatory Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 5: Anti-Inflammatory Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 6: Anti-Inflammatory Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017
Figure 7: Anti-Inflammatory Therapeutics Market, The US, Revenue ($bn), 2002-2017
Figure 8: Anti-Inflammatory Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017
Figure 9: Anti-Inflammatory Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2017
Figure 10: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2017
Figure 11: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Segmentation by Geography ($bn), 2002-2017
Figure 12: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017
Figure 13: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2002-2017
Figure 14: Anti-Inflammatory Therapeutics Market, Japan, Revenue Forecast ($bn), 2002-2017
Figure 15: Anti-Inflammatory Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017
Figure 16: Anti-Inflammatory Therapeutics Market, Japan, Treatment Usage Pattern (millions), 2002-2017
Figure 17: Respiratory Therapeutics Market, Global, Revenue ($bn), 2002-2017
Figure 18: Respiratory Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 19: Respiratory Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 20: Respiratory Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 21: Respiratory Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017
Figure 22: Respiratory Diseases Therapeutics Market, Drivers and Barriers, 2010-2017
Figure 23: Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2017
Figure 24: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 25: Arthritis Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 26: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 27: Arthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017
Figure 28: Arthritis Therapeutics Market, Market Drivers and Barriers, 2010-2017
Figure 29: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2002-2017
Figure 30: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 31: Multiple Sclerosis Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 32: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 33: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2017
Figure 34: Multiple Sclerosis Therapeutics Market, Drivers and Barriers, 2010-2017
Figure 35: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002-2017
Figure 36: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 37: Psoriasis Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 38: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 39: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017
Figure 40: Psoriasis Therapeutics Market, Drivers and Barriers, 2010-2017
Figure 41: Spondyloarthropathies Therapeutics Market, Global, Revenue ($bn), 2002-2017
Figure 42: Spondyloarthropathies Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 43: Spondyloarthropathies Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 44: Spondyloarthropathies Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 45: Spondyloarthropathies Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017
Figure 46: Spondyloarthropathies Therapeutics Market, Global, Drivers and Barriers, 2010-2017
Figure 47: IBD Therapeutics Market, Global, Revenue ($bn), 2002-2017
Figure 48: IBD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 49: IBD Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 50: IBD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 51: IBD Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2017
Figure 52: IBD Therapeutics Market, Global, Drivers and Barriers, 2010-2017
Figure 53: Gout Therapeutics Market, Global, Revenue ($m), 2002-2017
Figure 54: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017
Figure 55: Gout Therapeutics Market, Global, Revenue Segmentation, 2010-2017
Figure 56: Gout Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017
Figure 57: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017
Figure 58: Gout Therapeutics Market, Global, Drivers and Barriers, 2010-2017
Figure 59: Anti-Inflammatory Therapeutics Market, Global, R&D Pipeline by Indications, 2010
Figure 60: Anti-Inflammatory Therapeutics Market, Global, R&D Pipeline by Phase, 2010
Figure 61: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Abbott, 2011
Figure 62: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Amgen Inc., 2011
Figure 63: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Johnson & Johnson, 2011
Figure 64: Anti-Inflammatory Therapeutics Market, SWOT Analysis, GlaxoSmithKline, 2011
Figure 65: Anti-Inflammatory Therapeutics Market, SWOT Analysis, AstraZeneca, 2011
Figure 66: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Merck, 2011
Figure 67: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Pfizer, 2011
Figure 68: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Boehringer Ingelheim GmbH, 2011
Figure 69: Anti-Infllamtory Therapeutics Market, SWOT Analysis, Sanofi, 2011
Figure 70: Anti-Inflammatory Therapeutics Market, Global, Deals by Type, 2004-2011
Figure 71: Anti-Inflammatory Therapeutics Market, Global, Major Deals By Year, 2004-2011
Figure 72: Anti-Inflammatory Therapeutics Market, Global, Major Deals By Geography, 2004-2011
Figure 73: Anti-Inflammatory Therapeutics Market, Global, Major Deals by Value (%), 2004-2011
Figure 74:Anti-Inflammatory Therapeutics Market, Global, Licensing Deals By Year, 2004-2010
Figure 75: Anti-Inflammatory Therapeutics Market, Global, Licensing Deals By Geography, 2004-2011
Figure 76: Anti-Inflammatory Therapeutics Market, Global, Major Licensing Deals by Value (%), 2004-2011
Figure 77: Anti-Inflammatory Therapeutics Market, Global, Co-Development Deals By Year, 2004-2010
Figure 78: Anti-Inflammatory Therapeutics Market, Global, Co-Development Deals By Geography, 2004-2010
Figure 79: Anti-Inflammatory Therapeutics Market, Global, Major Co-Development Deals by Value (%), 2004-2010
Figure 80: GBI Research Market Forecasting Model

Abstract

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate”, which provides insights into anti-inflammatory therapeutics revenue forecasts until 2017. The report also examines the global anti-inflammatory treatment usage patterns. In addition, the geographical distribution of anti-inflammatory therapies across the US, the top five countries in Europe, and Japan is also provided in the report. The report also includes insights into the anti-inflammatory R&D pipeline. The report provides an in-depth analysis of the top seven inflammatory therapeutic indications, which are respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these seven therapeutic indications. The report also explores the competitive landscape, including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving anti-inflammatory treatments is also presented.

The in-depth analysis of the report is based on proprietary databases, primary and secondary research, and in-house analysis by the GBI Research team of experts.

GBI Research analysis showed that the global inflammatory therapeutics market was estimated at $57.8 billion in 2010, representing a cumulative annual growth rate of 7.6% between 2002 and 2010. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 5.8% between 2010 and 2017, to record a sales value of $85.9 billion. The patent expiry of some major drugs by 2017 is expected to make way for the entry of generics, whereas this impact will be reversed by a number of strong pipeline molecules.

GBI Research has segmented each section of the anti-inflammatory therapeutics market into branded and generics, and estimates the global inflammatory therapeutics to gain 73.1% of revenue from the branded market, whereas 26.9% was achieved from the generics market in 2010. Due to the presence of a strong pipeline portfolio for anti-inflammatories, the branded share is forecast to increase to 78.6% in 2017, and the generics market will decrease to 21.4%.

GBI Research analysis shows that the R&D pipeline for anti-inflammatory therapeutics is strong. Many of the major pharmaceutical companies such as Abbott, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Eli Lilly, Boehringer Ingelheim and Sanofi are either entering or expanding into the market. They are collaborating with or acquiring small and medium-sized enterprise (SME) pharmaceuticals, which have promising anti-inflammatory drugs in their pipeline. Currently, more than 1,000 molecules are in R&D, with 12% of them in Phase III, 36% in Phase II, 15% in Phase I, 29% in preclinical stage, and 7% in discovery phase. This indicates that anti-inflammatory R&D will be very active for at least the next seven to eight years. The main factor that is driving the big pharmaceutical companies towards the inflammatory therapeutics market is the large patient base. Respiratory diseases and arthritis continue to be some of the most common diseases and are among the leading causes behind major chronic disabilities in the workforce.

Scope
  • Data and analysis on the inflammatory therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the inflammatory therapeutics market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Analysis of the leading therapeutic segments, including respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout.
  • Key drivers and restraints that have a significant impact on the market.
  • The competitive landscape of the global inflammatory therapeutics market, including top companies benchmarking. The key companies studied in this report are Abbott, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Eli Lilly, Boehringer Ingelheim and Sanofi.
  • Key M&A activities and Licensing Agreements that took place in 2004 and 2010 in the inflammatory therapeutics market.
Reasons to buy
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.